Comparison of intermittent intravenous and oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients: A meta-analysis of randomized controlled trials

Clinical Nephrology

Volumn 71, Issue 3, 2009, Pages 276-285

  Zhou, Haiyang ^a   Xu, Chenggang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Calcitriol; Intravenous; Meta analysis; Oral; Secondary hyperparathyroidism

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PHOSPHORUS; PLACEBO; VITAMIN;

ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION ROUTE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; INCIDENCE; LONG TERM CARE; META ANALYSIS; PARATHYROID HORMONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; SENSITIVITY ANALYSIS; TREATMENT DURATION; VOMITING; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; HYPERPARATHYROIDISM; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; RENAL REPLACEMENT THERAPY; RISK;

ADMINISTRATION, ORAL; CALCITRIOL; CONFIDENCE INTERVALS; HUMANS; HYPERPARATHYROIDISM; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; VITAMINS;

EID: 65449185406     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71276     Document Type: Article

References (30)

1. Andress DL. Intravenous versus oral vitamin D therapy in dialysis patients: what is the question? Am J Kidney Dis. 2001; 38 (Suppl 5): 41-44.
2. Ardissino G et al. No difference in intestinal strontium absorption after oral or i.v. calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure. Kidney Int. 2000; 58: 981-988.
3. Bacchini G et al. "Pulse oral" versus intravenous calcitriol therapy in chronic hemodialysis patients. Nephron. 1997; 77: 267-272.
4. Borazan A et al. Comparative efficacy of oral and intravenous calcitriol treatment in haemodialysis patients: effects on serum biochemistry and cytokine levels. J Int Med Res. 2003; 31: 489-496.
5. Caravaca F et al. Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 1995; 10: 665-670.
6. Faugere M-C et al. Efficacy and limitation of pulse i.v. and pulse oral 1,25 vitamin D therapy on bone disease in patients on chronic dialysis (abstract). J Am Soc Nephrol. 1993; 4: 695.
7. Fischer ER, Harris DCH. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol. 1993; 40: 216-220.
8. 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993; 92: 1436-1443.
9. Indridason OS, Quarles LD. Oral versus intravenous calcitriol: is the route of administration really important? Curr Opin Nephrol Hypertens. 1995; 4: 307-312.
10. Indridason OS, Quarles LD. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int. 2000; 57: 282-292.
11. Jadad AR et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Contr Clin Trials. 1996; 17: 1-12.
12. Kjaeragard LL et al. Reported methodologic quality and discrepancies between large and small randomized trials inmeta-analyses. Ann Intern Med. 2001; 135: 982-989.
13. Levine BS, Song M. Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol. 1996; 7: 488-496.
14. Lin SY et al. Effect of intravenous calcijex on secondary uremic hyperparathyroidism: a multicenter clinical trial. Shanghai Med J (Chin). 1999; 22: 518-521.
15. Liou HH et al. Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients. Miner Electrolyte Metab. 1994; 2: 97-102.
16. Liu YQ et al. Effect of the mode of calcitriol administration on chronic renal failure patients with secondary hyperparathyroidism. Chin J Blood Purif (Chin). 2002; 1: 17-20.
17. Maki DD et al. Long-term effects of antihypertensive agents on proteinuria and renal function. Ann Intern Med. 1995; 155: 1073-1080.
18. Mazess RB, Elangovan L. A review of intravenous versus oral vitamin D hormone therapy in hemodialysis patients. Clin Nephrol. 2003; 59: 319-325.
19. Oettinger CW et al. The effects of calcium carbonate as the sole phosphate binder in combination with low calcium dialysate and calcitriol therapy in chronic hemodialysis patients. J Am Soc Nephrol. 1992; 3: 995-1001.
20. Peng SJ et al. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients. Miner Electrolyte Metab. 1997; 23: 13-18.
21. Quarles LD et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. 1994; 45: 1710-1721.
22. Seidel A et al. Kinetics of serum 1,84 iPTH after high dose of calcitriol in uremic patients. Clin Nephrol. 1993; 39: 210-213.
23. Sherrard DJ et al. The spectrum of bone disease in end stage renal failure - An evolving disorder. Kidney Int. 1993; 43: 436-442.
24. Silver J. What stimuli control the activity of the parathyroid cell? Nephrol Dial Transplant. 1995; 10: 599-600.
25. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant. 1996; 11 (Suppl 3): 130-135.
26. 3 were given by same dose in hemodialysis patients with secondary hyperparathyroidism. J Postgrad Med (Chin). 2001; 24: 15-17.
27. Susanna F et al. Treatment of secondary hyperparathyroidsism with low-dose intermitent calcitriol in hemodialysis patients. Imaging and cost analysis. ASAIO J. 1995; 41: 688-693.
28. 3 inhibits parathyroid cell proliferation in experimental uremia. Kidyney Int. 1989; 35: 1049-1056.
29. Teng M et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005; 16: 1115-1125.
30. Turk S et al. Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone mineral density. Nephron. 2002; 90: 188-194.